The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it remained in positive territory through November, up 3.58%, the steady decline through the later months of the year pushed the index into the red by December’s close.

The map of cystic fibrosis (CF) research is being redrawn in the U.K. as improvements in treatment, and in particular the introduction of CF modulator drugs, mean people with the rare inherited disease are living much longer.

A panel at Biocom California’s 15th Annual Global Life Science Partnering & Investor Conference covered the emerging use of artificial intelligence (AI) to discover and develop drugs. “We’re in a very different place than we were five years ago, or even three years ago, even two years ago, from our ability to harness AI to make advances,” Marc Tessier-Lavigne, CEO of South San Francisco-based Xaira Therapeutics Inc., told the audience, adding that the development is actually accelerating.

HBM Alpha Therapeutics Inc. signed a potential $395 million licensing deal Feb. 26 with an unnamed “business partner” for its endocrine asset, HAT-001, adding another contender to the congenital adrenal hyperplasia space.

Several Asia biotechs this week – including Innocare Pharma Ltd., Akeso Pharmaceuticals Inc., Sanbio Co. Ltd. and Ascletis Pharma Inc. – unveiled the start of new late-stage clinical trials or interim findings from early stage studies.

As Wall Street looks ahead to phase III data due soon with Mineralys Therapeutics Inc.’s lorundrostat for uncontrolled or resistant hypertension, analysts are also weighing the odds of the firm in phase II with the same compound for obstructive sleep apnea.

Despite the number of med-tech deals increasing to 1,902 in 2024, up 12% from 1,701 in 2023, the value of these deals has dramatically declined compared to previous years.

The BioWorld Infectious Disease Index (BIDI) faced challenges throughout the year but narrowed its losses, ending down 6.28% after hitting a low of -25.12% in late April. By October, the index was down 12.07% and had declined 8.86% for the year as of Nov. 22. However, in January, the BIDI rebounded slightly, gaining 1.85%.